General description
A cell-permeable quinoxaline-carboxylic acid compound that acts as a selective PAS kinase/PASK inhibitor (IC50 ~ 4 nM) with little or no potency against a panel of 49 other kinases (IC50 ≥ 10 µM) and effectively inhibits cellular PASK-T307 autophosphorylation (IC50 ~ 1 µM; 16 h drug treatment in PASK-transfected HEK293T cultures with 1% FBS). Similar to siRNA-mediated PASK knockdown, BioE-1115 treatment is shown to effectively prevent sterol regulatory element binding protein SREBP-1c maturation without affecting Akt/mTOR pathway signaling, resulting in impaired cellular SREBP transcription activity in HepG2 cultures (% inhibition/[drug] = 40%/30 µM & & 65%/50 µM by SRE-Luc reporter assay; overnight drug treatment prior to 100 nM insulin stimulation for 6 h). Oral administration is reported to effectively reduce high-frucose diet/HFrD-induced dyslipidemia (% reduction of liver triglyceride/serum triacylglyerol/dose = 48/26/30 mg kg-1 & 63/55/100 mg kg-1; Daily oral dosage administered in the last wk of a 3 wk HFrD period, followed by a 24 h fasting and a 12 refed period prior to tissue collection) and insulin resistance (% reduction of serum glucose/insulin/dose = 23/14/30 mg kg-1 & 28/31/100 mg kg-1) in rats by selectively suppressing SREBP-1 maturation and thereby inhibiting SREBP-1c, but not SRREBP-2, target genes transcription in liver, but not in abdominal fat or gastrocnemius muscle in vivo (% Gpat1/Fasn/Scd1/Acc1/Fae mRNA reduction/plasma [BioE-1115] in µg/mL/dose = 40/34/36/27/34/2.07/10 mg kg-1, 59/56/51/48/54/7.65/30 mg kg-1, 76/5967/62/74/42.2/100 mg kg-1) without affecting liver or body weight.
A cell-permeable, orally available, non-toxic quinoxaline-carboxylic acid based compound that acts as a highly potent, selective, and reversible inhibitor of Per-Arnt-Sim Kinase (PASK; IC50 ~ 4 nM). Exhibits excellent selectivity over 49 other kinases (IC50 >10 µM) and displays about 2,500-fold greater potency for PASK over casein kinase 2α. Blocks PASK autophosphorylation at Thr307 in a dose-dependent manner (IC50 ~ 1 µM) without affecting the insulin-induced phosphorylation of either Akt or S6K. Effectively blocks the maturation of SREBP-1 in hepatic tissue of high fructose fed wild-type Sprague-Dawley rats. Shown to normalize hepatic and serum triglyceride levels, reduce blood glucose levels, and partially reverse insulin resistance in animal models (30 mg/kg. p.o.).
Please note that the molecular weight for this compound is batch-specific due to variable water content.
BioE-1115, PASKi
Biochem/physiol Actions
Cell permeable: yes
Primary Target
PASK
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Wu, X., et al. 2014. Cell Rep.8, 242.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Molecular Weight: 339.36. Empirical Formula: C19H18FN3O2. Assay: ≥. 97% (HPLC). Quality Level: 100. form: powder. manufacturer/tradename: Calbiochem®. . storage condition: OK to freeze, protect from light. color: yellow. solubility: DMSO: 50 . mg/mL. storage temp.: 2-8°C. Storage Class Code: 11 - Combustible Solids. WGK: WGK 3. Flash Point(F): Not applicable. Flash Point(C): Not applicable.- UPC:
- 12352204
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 5323060001